FIELD: pharmaceuticals.
SUBSTANCE: group of inventions includes a method for preparing a drug based on oligopeptide alloferon, having an antiviral and immunomodulating directivity, characterized by preparation of a drug composition containing alloferon in concentration of 1 mg/ml, dissolved in a medium of the composition: 0.9 % solution of sodium chloride based on light water "Langwei" in phosphate or acetate buffer with pH from 6.0 to 7.5, characterized by that the composition is previously gas-saturated by bubbling, neutral to oligopeptides of alloferon, until solution is obtained, which composition at room temperature has dynamic viscosity of not more than 1.007 mPa-s and total density of 1.0063 g/cm3, after which the ready solution is bottled with vials or ampoules at constant blowing with gas. Second invention of the group is a drug in the form of a solution based on oligopeptide alloferon extended storage life.
EFFECT: technical result is longer shelf life of ready-to-use solution.
4 cl, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION CONTAINING BIOLOGICALLY ACTIVE ALLOFERON AND ZINC COMPLEXES AND METHOD OF PRODUCTION THEREOF | 2019 |
|
RU2742565C1 |
METHOD OF TREATING PAPILLOMA VIRAL INFECTIONS IMPLEMENTED THROUGH INTERLEUKIN-18 INDUCTION | 2010 |
|
RU2482866C2 |
COMPOSITION FOR PREPARATION OF ANTI-TUMOR MEDICATION AND METHOD FOR PREPARATION OF ANTI-TUMOR MEDICATION BASED ON IT | 2016 |
|
RU2667128C2 |
AGENT FOR EXTERNAL USE WITH ANTIVIRAL ACTION | 2021 |
|
RU2819719C2 |
METHOD OF COMPLEX THERAPY OF PRE-INVASIVE AND INVASIVE CERVICAL CANCER | 2013 |
|
RU2560689C2 |
BIOLOGICALLY ACTIVE DERIVATIVES OF ALLOFERON-1 | 2013 |
|
RU2576830C2 |
BIOLOGICALLY ACTIVE PEPTIDES | 2013 |
|
RU2575069C2 |
ALLOPHERONES AS IMMUNOMODULATING PEPTIDES | 1999 |
|
RU2172322C1 |
METHOD FOR TREATMENT OF ALEUTIAN MINK DISEASE | 2020 |
|
RU2742160C1 |
AGENT FOR EXTERNAL APPLICATION, POSSESSING ANTIVIRAL ACTIVITY | 2006 |
|
RU2338553C2 |
Authors
Dates
2020-12-03—Published
2017-12-28—Filed